The latest news updates from the 2024 Symposium
-
Results from EMERALD trial and key findings from PI3K pathway inhibitor study presented at #SABCS21
Read More: Results from EMERALD trial and key findings from PI3K pathway inhibitor study presented at #SABCS21Wednesday’s General Session featured new data about the oral SERD elacestrant and the effect of tamoxifen on uterine cancer risk.
-
McGuire Award Lecture: Moving to precision care in breast cancer
Read More: McGuire Award Lecture: Moving to precision care in breast cancerOlufunmilayo I. Olopade, MD, FAACR, recounted her lifelong journey through breast cancer genomics during the William L. McGuire Memorial Lecture on Wednesday.
-
Regulatory session covers latest breast cancer treatment approvals
Read More: Regulatory session covers latest breast cancer treatment approvalsA special session on Wednesday reviewed the Food and Drug Administration’s recent approval of pembrolizumab for neoadjuvant and adjuvant treatment, and abemaciclib in the adjuvant setting.